Fig. 6

SRC and HER2 inhibitors increase endocrine sensitivity of HCC1428 cells expressing endogenous ESR1–CCDC170 fusion. a Sensitivity of HCC1428 cells to tamoxifen in combination with selective targeted agents as measured by clonogenic assays. HCC1428 cells were treated with different dosages of 4-OH tamoxifen (μM), or 4-OH tamoxifen plus lapatinib (2 μM), dasatinib (0.05 μM), BEZ235 (8 nM), or AZD8931 (1 uM). Data were normalized against vehicle treatment alone (as 100%). b Sensitivity of HCC1428 cells to fulvestrant in combination with selective targeted agents as measured by clonogenic assays. HCC1428 cells were treated with different dosages of fulvestrant (μM), or fulvestrant plus lapatinib (2 μM), dasatinib (0.05 μM), BEZ235 (8 nM), AZD8931 (1 uM), or lapatinib (2 μM) + dasatinib (0.05 μM). Data were normalized against vehicle treatment alone (as 100%). Tam, 4-OH tamoxifen; Ful, fulvestrant, Lapa, lapatinib; Dasa, dasatinib, BEZ, BEZ235, AZD, ZAD8931. ***P < 0.001 (two-way ANOVA)